Eli Lilly shares jump as weight-loss drug sales top expectations

Eli Lilly raised its full-year earnings forecast as demand for its weight-loss drugs lifted sales, according to the New York Post. The paper said sales of Mounjaro and Zepbound each exceeded expectations by more than 5%, strengthening the company’s position in the obesity-drug market.

Reuters and RTÉ headlines also reported that Lilly raised its outlook on weight-loss drug sales; Reuters’s headline described demand for its weight-loss shot as soaring. Lilly’s shares climbed 6%, and the New York Post put the company’s valuation at $1.3 trillion. GuruFocus’s headline said Lilly reached a record high, but did not specify a share-price figure.

The New York Post also cited Reuters for a comparison with Novo Nordisk, the maker of Wegovy, which it said had a valuation of about $171 billion. The New York Post said Lilly’s recent acquisitions of AtaiBeckley and Curevo reduced its profit outlook. It attributed that account to Reuters.

The article quoted Halter, a shareholder who owns more than 16,000 Lilly shares, saying the company was spending money now to make money in the future. The excerpt does not quantify the acquisitions’ effect on earnings or give details of the deals.

The article also cited separate study results for oral weight-loss drugs: users of oral Wegovy lost about 14% of their body weight over 64 weeks, while patients taking Foundayo lost roughly 11% over 72 weeks. Those figures describe the reported study outcomes; the excerpt does not give study designs or further comparisons between the medicines.

The company’s raised earnings forecast and the reported sales figures are the central financial developments. The New York Post linked the forecast increase to Lilly’s weight-loss drug sales, while its account also noted acquisition-related costs as a drag on the profit outlook.

Reuters and RTÉ headlines characterized the outlook change as a revenue increase, while the Financial Times headline framed the story around rising profits. The accounts do not provide the updated forecast figures or specify how much revenue or profit the medicines generated.

The New York Post’s report supplies the sales comparison, share movement, valuation figures, acquisition information and study results; the other outlet headlines offer narrower descriptions of the outlook change, stock movement, record high and profit surge.